Growing up in rural areas, having younger parents, and having less education may all be environmental risk factors for ALS, ...

Worrying about symptom progression a year after her diagnosis, columnist Dagmar Munn decided to develop her own resilience ...

The U.S. Food and Drug Administration (FDA) signaled that it may be willing to consider granting accelerated approval to ...

MN-166 (ibudilast) appears to benefit ALS patients over up to one year of use, an interim Phase 2b/3 trial analysis suggests.

The first ALS patient was dosed in a Phase 1 trial of Quralis' first-in-class therapy QRL-101, which is still enrolling at a ...

Data from over 8,000 ALS patients will be fed into Unlearn's Digital Twin Generator, an AI platform that creates duplicates ...

The results of CardinALS showed utreloxastat failed to meet its main and secondary goals, including several disease-related ...

MaaT033, an experimental oral therapy for improving gut microbiome health, was shown to be safe and well tolerated in ALS ...

Neuralink's brain-computer interface will be tested in Canada, with Toronto's University Health System seeking patients for ...

Columnist Dagmar Munn has managed the shift to a rollator, scooter, and other assistive devices that help her live a better ...

Columnist Dagmar Munn has a Santa wish list for her outings over the holidays: accessible restrooms and good cutlery among ...

Scientists studied 188 people related to someone with ALS caused by a C9ORF72 mutation to identify markers of disease risk in ...